Asst-Monza Ospedale San Gerardo
Monza, Lombardy, 20900, Italy
NCT Number: NCT05008380
The study aims to evaluate if the early prone-positioning in awake patients with mild Covid-19 pneumonia can reduce the need of high-flow oxygen-therapy, invasive or non-invasive ventilation and prevent the worsening of clinical conditions.
Patients will be randomized on a 1:1 ratio and stratified based on the onset of symptoms (<10 days; >10 days) and need of oxygen therapy (no need; need).
One branch of patients (interventional) will undergo standard of care treatment + prone-positioning cycles, the other one (controll) will undergo standard of care treatment alone.
Patients will be evaluated evaluated on the day of the enrolment, on day 1, day 3, day 7 and every 7 days until the patient dismissal or until day 28 (whichever occurs first).
Adverse events and concurrent medications will be noted as well.
The analysis will be conducted according to "intention to treat" criteria; primary outcomes will be calculated using survival-based methods.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Monza, Lombardy, 20900, Italy
In this prospective, unicentred, open, controlled study, patients will be randomized on a 1:1 ratio using casual permutation blocks, identifying two branches of treatment: standard of care; standard of care + prone positioning. Patients will be stratified in 4 strata based on the onset of symptoms (<10 days; >10 days) and need of oxygen therapy (no need; need).
In order to obtain statistical significance, the sample size will include 96 patients.
Patients in the SOC + prone-positioning branch will undergo cycles of prone-positioning following this scheme: 3-6 hours of prone-positioning twice a day. The actual length of the cycles will be registered during the study.
Data will be collected using a dedicated CRF, which will include recording of adverse events and concurrent medications.
Patients will be evaluated on the day of the enrolment, on day 1, day 3, day 7 and every 7 days until the patient dismissal or until day 28 (whichever occurs first). If dismissal occurs before day 28, a follow-up interview will be conducted in presence or on the phone to collect the remaining data.
The analysis will be conducted according to "intention to treat" criteria; primary outcomes will be calculated using survival-based methods (Kaplan-Meier curves with log-rank test and Cox regression), while secondary outcomes will be evaluated using both survival-based methods and proportional odds model.
The occurrence of adverse events and the causes of withdrawal from the study in the two branches of treatment will be compared using chi-square test.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
3-6 hours of prone-positioning twice a day
Time frame: 0-28 days
the occurence of the first of the following end-points: death, start of high flow oxygen therapy, CPAP, meccanichal ventilation, P/F <200
Time frame: 0-28 days
Time frame: 0-28 days
Time frame: 0-28 days
Time frame: 0-28 days
Time frame: 0-28 days
Time frame: 0-28 days
University of Milano Bicocca
Other
Open-label, Controlled, Randomized Clinical Trial on the Efficacy of Early Prone-positioning in Patients With Mild Pneumonia Due to SARS-CoV-2
Acronym: EpCOT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05765396
COVID-19, COVID-19 Pneumonia
Fort Sam Houston, Texas, United States
View Trial DetailsNCT07656610
COVID-19, COVID-19 Pneumonia
Çorum, Turkey (Türkiye)
View Trial DetailsNCT05392075
COVID-19, COVID-19 Pneumonia
Dallas, Texas, United States
View Trial DetailsNCT04615429
Acute Respiratory Distress Syndrome, COVID-19 Pneumonia
Majadahonda, Madrid, Spain
View Trial Details